Work Advice: Should you list a job you got fired from on a résumé?

Reader: My son was just fired after four months at a new job he had relocated for. It was pretty much his own fault. There was a long lapse in his health insurance and he didn't do what he needed to do to secure his ADHD meds. As a result, he made errors that cost the company money.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

36 minutes ago

• Yahoo

A longer ‘winter': Public funding slowdown heightens pressure on biotech startups

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Biotechnology industry watchers were hopeful at the start of 2025. Venture funding appeared to be rebounding after a lengthy slump, and a smattering of new stock offerings and company acquisitions brewed optimism that the public markets might be similarly warming up to young drugmakers. But the positivity quickly dissipated. Trump administration policies gutted scientific research funding and raised questions about U.S. drug prices. Large layoffs and upheaval at public health agencies created regulatory turmoil that added risk to what's already, by its nature, a risky sector to invest in. The results were laid out in a June report from David Windley and Tucker Remmers, two analysts at the investment bank Jefferies. According to that report, funding in public biotech companies — be it from initial public offerings, follow-on stock offerings, or 'PIPE' deals — plummeted in May. The 'political and economic uncertainties' have "cast a cloud over biotech investment,' they wrote. 'Since product development cycles can range 12-15 years in this industry, biotechs (and their boards and investors) want clarity on FDA regulation, drug pricing, and funding before committing to large, [long-term] investments,' Windley and Remmers wrote. Investors and industry insiders interviewed by BioPharma Dive say that the public slowdown is trickling down to startups that have already been under intense pressure during a prolonged pullback. Companies and investors are struggling to align on valuations, making funding rounds more difficult to close than in prior years. The uphill battle in the public markets is further delaying IPO plans, too. "People are waiting to see what happens, and it's extended that winter," said Tim Scott, the president of Biocom California, an industry trade group. To date, only seven biotech companies have priced IPOs in 2025, and no large offerings have occurred since mid-February. No biotechs have publicly disclosed IPO ambitions in several months either, and one of the last to do so, Odyssey Therapeutics, pulled its offering in May. In a letter to the Securities and Exchange Commission, CEO Gary Glick wrote that it was 'not in the best interests of the company' to go public at that time. One reason IPOs have ground to a halt, experts say, is that the public markets aren't rewarding drug startups as predictably as they once were. Typically, drug companies can expect their value to climb after delivering positive clinical results. But 'even companies with good data aren't seeing a lot of movement in the public markets,' said Jonathan Norris, a managing director at HSBC Innovation Banking. As a result, Norris said, companies are looking at the time and expense it takes in the monthslong process to go public and wondering: 'What's the benefit?' 'If you have any readouts that are even eye squinting, you're going to get crushed,' he said. 'It's a tough, tough endeavor.' The shuttered IPO window is exacerbating problems for young biotechs. "If you don't have a public market opportunity, then the companies that are private have to think about ways to raise capital and stay private for longer," said Maina Bhaman, a partner at Sofinnova Partners. Feeling that burden, venture investors are becoming more conservative. While private funding hasn't plummeted as much as its public counterpart, investors are more selective and slower-moving. Funding has become increasingly consolidated into fewer and larger 'megarounds,' to the extent that more firms are compiling similar portfolios. And they're hard to finalize, even when most of a funding syndicate is already onboard, according to Norris. "People are struggling to figure out where the bottom of the market is and what's the appropriate valuation and expectation for that investment,' he said. "A lot of VCs are pencils down right now on deals they would otherwise be moving forward on,' Scott added. Pullbacks are nothing new in biotech. But what has been unusual, some say, is how long the sector has spent in the doldrums after peaking in early 2021. One reason is the most recent boom flooded the market with more companies than it could support. But another is that the ensuing correction has intensified amid regulatory and political upheaval. A report last week from Roel van den Akker, PwC's U.S. pharma and life science deals leader, predicted that companies will be 'preparing contingency plans' to account for delays in 'trial oversight' and drug applications. Drug companies are used to dealing with a high level of risk, as most experimental medicines never make it to market. But 'now you've got a lot more macro uncertainty that is being layered on top," Bhaman said. On the public side, that uncertainty has resulted in less patient investors, some of whom are pressing company boards to shut down after setbacks rather than change course. But some startups are taking drastic steps, too, such as cutting programs and staff to, some experts believe, depress their value so they can still attract investment. The "lack of surety" is pressuring biotechs to be as efficient as possible with their cash, Scott said, perhaps working on one program instead of a few. There have been multiple high-profile examples of late. Eikon Therapeutics and Insitro, two well-funded startups, both cited a need for 'prudence' in laying off staff. Norris expects more companies to proactively cut staff, or even close, as the longer-than-expected winter drags on. 'Most of those companies are not going to find the investors that they're hoping for,' he said. 'And I think that's just the unfortunate truth.' Recommended Reading Radiopharmaceutical drugmaker RayzeBio signals plans to go public

Yahoo

36 minutes ago

• Yahoo

Should You Forget Medical Properties Trust and Buy These Unstoppable Dividend Stocks Instead?

Medical Properties Trust has a 7.2% yield and a history of dividend cuts behind it. Other healthcare REITs have high yields and dividends that have withstood adversity much better. Omega Healthcare has a 7.4% yield, and LTC Properties has a 6.5% yield. 10 stocks we like better than Medical Properties Trust › Medical Properties Trust (NYSE: MPW) has a lofty 7.2% yield. That compares to the S&P 500 index's skinny little 1.2% yield, and the average real estate investment trust's (REIT's) yield of around 4.1%. On the surface, it appears to be an obvious choice. But don't jump at the chance to buy Medical Properties Trust just yet. You can get similarly large yields from healthcare REIT peers Omega Healthcare (NYSE: OHI) and LTC Properties (NYSE: LTC), and both offer a more compelling dividend story than Medical Properties. Here's what you need to know. Take a look at the chart below for Medical Properties Trust. The orange line is the quarterly dividend, and the purple line is the stock price. Notice the massive drop in both that has occurred since 2022. That was when some of the REIT's large tenants started to experience financial troubles. It was the start of a tense and complicated period when a small number of Medical Properties Trust's tenants failed, and it had no choice but to cut its dividend. For long-term dividend investors, the lofty 7.2% yield on offer from Medical Properties Trust comes with some lofty risks. It's possible that the bad news is all out, and the REIT can start to turn its business around. However, that's far from a certainty. Unless you're willing to bet that the future will look much brighter from here, most dividend investors will probably want to tread with caution. In fact, even if a turnaround is underway, it's likely to be a years-long process. There's a contrast to be made here with healthcare REITs Omega Healthcare and LTC Properties. Both of these REITs focus on senior housing, including nursing homes and assisted living facilities. During the coronavirus pandemic's height, both of these property types were hard hit. The reason was pretty simple: COVID-19 is particularly deadly for unvaccinated older adults and spreads easily in group settings. Occupancy fell for both REITs, and there was a drought of new customers. Both Omega and LTC also had to deal with tenant problems, as some of their lessees had trouble paying rent. That would seem like a perfect storm that would lead to a dividend cut. Yet neither Omega nor LTC cut their dividends. To be fair, neither of these REITs has increased their dividends in years. But a static dividend is much better than a dividend cut. Right now, Omega's yield is 7.4%, while more diversified LTC Properties has a 6.5% yield. The future is starting to look brighter for each of these healthcare REITs. Omega's adjusted funds from operations (FFO) rose year over year in the first quarter of 2025, and it increased its full-year guidance. LTC Properties, meanwhile, expects 2025's adjusted FFO per share to be flat to slightly higher. However, it's diversifying its business approach to include senior housing operating properties (SHOP). (SHOP assets are owned and operated by the REIT, though it actually hires a third party to handle day-to-day management of the asset.) As it grows, this business should increasingly benefit from the growth in demand for senior housing as the U.S. population ages. The key takeaway here, however, is that, when faced with adversity, Omega and LTC Properties held firm in their commitment to shareholders. They adjusted as needed to keep paying. Medical Properties Trust, on the other hand, couldn't manage that feat. The past doesn't predict the future, of course, but the past is all we have to go on as investors. And since all three of these healthcare REITs have faced material adversity just recently, their strengths and weaknesses have been laid bare. While the worst might be over for Medical Properties Trust, most dividend investors should probably err on the side of caution with either Omega, which has a higher yield, or LTC Properties, which has a lower yield but a far more diversified business model. Before you buy stock in Medical Properties Trust, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Medical Properties Trust wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Should You Forget Medical Properties Trust and Buy These Unstoppable Dividend Stocks Instead? was originally published by The Motley Fool Sign in to access your portfolio

Forbes

an hour ago

• Forbes

Why Gen Z Chooses Healthcare Over Tech: A Recruiting Blueprint

Doctor, woman and tablet in hospital with holographic ux for telehealth, medical innovation and dna ... More study. Medic, mobile touchscreen for typing on app for data analysis, 3d hologram ui and research A recent study at the National Society of High School Scholars (NSHSS) has revealed a profound shift in career aspirations among younger professionals, with 3 out of 4 young Americans (Gen Z) now choosing the essential and purpose-driven world of healthcare over high-tech jobs. This isn't just a trend, it's a wake-up call for industries challenged with workforce instability, the rise of automation, and shifting generational priorities. To explore this phenomenon more deeply, I interviewed four exceptional people and future healthcare leaders, who graduated from Cornell University's Sloan Master's in Health Administration program. Through their insights, we gain a richer understanding of what fuels this generational realignment and how other industries should consider adapting to remain relevant for an employee that knows what they want, how they want it. Redefining a Meaningful Career The pursuit of meaningful work was a common thread during our discussion. For Keshaav Krishnaa Pothapur, an incoming administrative fellow at Boston Medical Center, "a meaningful career is at the intersection of empathy and impact." Having started his career as a dentist, he quickly realized the limitations of addressing individual care and pivoted toward roles where he could influence systems and communities on a larger scale. 'There are more things to fix than people's teeth,' he remarked, underscoring the draw of systems-level change and his drive to make the healthcare experience more compassionate and effective. Similarly, Lesly Leon, bound for an administrative fellowship at Kaiser Permanente in Northern California, emphasized the duality of personal and community growth in a meaningful career. Growing up in underserved communities, Lesly experienced first-hand the challenges of accessing quality care. Her values now inform her mission to work within healthcare to improve equity and uplift populations facing similar barriers. 'Healthcare allows me to give back to the communities that shaped me,' she shared, connecting her personal experiences to her professional ambitions. Natalie Stopfer, who transitioned from a career as a behavioral health nurse to now, an Associate Consultant at Chartis noted the personal motivation of meaningful work. 'I always wanted to help people, even as a kid when I stocked my desk with band-aids to help classmates,' Natalie shared with a laugh. But her career isn't just about fulfilling childhood dreams, it's about finding joy and excitement in her work every day. For Natalie, a meaningful career is one that nourishes self-growth while also enabling her to improve patient care systems at a macro level. Deevena Annavarjula, manager of value-based care at Boston Medical Center, views meaningful work as engaging with the idea of evolution. 'Our work life takes up so much of our time. It has to be something we get excited about.' Balancing personal fulfillment with professional purpose, she is highly self-aware and mindful of carefully assessing and pivoting whenever workplace environments fail to align with her values. Her confidence in evolving roles and industries is a testament to Gen Z's innovative approach to career satisfaction. Stability in Healthcare Is About More Than Job Security Traditional notions of stability, holding one job at one company for the entirety of a career, are a thing of the past for Gen Z. Lesly noted that while healthcare offers career stability through essential, purpose-driven work, 'there can often be a disconnect between expectation and reality,' particularly regarding the emotional toll of the job. Having witnessed her own mother's struggle to access adequate care, Lesly believes that reshaping healthcare to be more equitable will not only meet societal needs but also provide new generations of healthcare professionals with fulfilling roles that endure. This contrasts sharply with the instability affecting tech industries. Companies like Amazon have publicly acknowledged how AI advancements are leading to significant job cuts, creating anxiety among employees about their future roles. Amazon's own CEO Andy Jassy recognized that automation is reshaping the workforce, drawing critical attention to the growing gap in job stability in the tech sector. For healthcare professionals, such turbulence in other industries underscores the appeal of a field rooted not just in purpose but also in necessity. Deevena took the concept further, explaining that for her, stability stems from adaptability. 'It's not about staying in one job for 40 years anymore. What matters is knowing you can find your place at every phase of your career.' For her, life transitions, including moving from the insurance industry to hospitals and continuously applying skills in new ways are part of what keeps her engaged. This mindset reflects a broader trend amongst younger professionals seeing stability not as rigidity but as flexibility to grow and thrive in dynamic environments. Keshaav added another dimension by tying adaptability to the evolving innovation in healthcare. He noted that the pandemic catalyzed a shift in how healthcare is viewed, moving it from being a reactive system to one that embraces innovation. 'Tech is powerful, but healthcare is essential,' Keshaav stated. For younger professionals, stability goes beyond a steady paycheck to include opportunities to contribute to cutting-edge solutions, such as predictive algorithms and AI, which are reshaping care research and care delivery. Gen Z Is Reshaping Mentorship Dynamics One of the most striking insights from the panel was their take on mentorship. Traditionally viewed as a one-way relationship, Gen Z professionals no longer see mentors solely as providers of wisdom. Instead, mentorship has evolved into a dynamic, two-way exchange. 'Having a mentor is like having your own Google Translate for workplace jargon,' Keshaav explained, emphasizing the role mentors play in decoding the complexities of healthcare for new professionals. However, mentors also learn from their mentees. As Deevena pointed out, 'This isn't the first time healthcare has faced significant changes. Mentors help us see how challenges were addressed in the past while we offer fresh ideas for navigating today's transitions.' Lesly underscored the importance of understanding traditional structures while working toward necessary changes. 'Mentorship is a collaborative process. Even when there's a gap between generations, there's always an opportunity to learn from one another.' For Natalie, her mentors helped repurpose her clinical nursing experience to improve healthcare systems at a higher, strategic level. These dynamic relationships enrich both generations by bridging experience with innovation. Lessons for Other Industries If healthcare has become a destination for young professionals seeking purpose and stability, what can other industries learn from this shift? The answer lies in fostering environments where connections are meaningful, opportunities for growth are abundant, and individual values and beliefs are honored. Industries like tech, currently grappling with AI-driven workforce reductions, such as the cuts Amazon has disclosed, would do well to adopt some of Keshaav, Lesly, Deevena and Natalie's insights. A Call to Action for Leaders Everywhere The stories shared by these future healthcare leaders with a path forward, not just for hospitals, but for any organization striving to attract and retain Gen Z talent. Industries must evolve from transactional workplaces to environments that are transformational for both the individual and society. With this in mind, here are five key imperatives leaders need to act on today: A Future Built on Purpose and Community If industries like tech and beyond hope to remain competitive, they must ask themselves hard questions. Are they creating environments where young professionals can challenge norms, grow their skills, and thrive despite technological disruption? Are they actively aligning workplace values with the aspirations of the workforce? Without these considerations, all industries risk alienating a generation that sees purpose not as an option, but as a norm. The future belongs to sectors and leaders brave enough to prioritize innovation, purpose, and community for a Gen Z workforce that knows what they want.